Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)
Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Elisabeth Gardiner(Saudi Aramco (United States)), Virginia Bayer(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Kathryn Lito(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Kelly Rangel(The University of Texas MD Anderson Cancer Center), Karen Lu(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor
|Nature Nanotechnology|2008|3.6k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Paraneoplastic Thrombocytosis in Ovarian Cancer
|New England Journal of Medicine|2012|822